Monopar Therapeutics Inc.
MNPR | NASDAQ
$95.72
-$0.75 (-0.78%)
At close: Sep 21, 2026, 4:00 PM ET
$96.15
+$0.43 (+0.45%)
Pre-market:
Sep 22, 2026, 5:56 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -16.7M | -16.16M | -8.83M | -10.54M | -9.13M | -6.51M |
Interest Income | 2.99M | 404.02K | 429.04K | 21.24K | 24.02K | 81.9K |
Pretax Income | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M |
Net Income | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M |
Selling & General & Admin | 6.8B | 3.16M | 3.23M | 2.95M | 2.63M | 2.44M |
Research & Development | 9.9B | 13.01M | 5.6M | 7.59M | 6.49M | 4.07M |
Other Expenses | -16.69B | n/a | n/a | n/a | n/a | 0 |
Operating Expenses | 16.7M | 16.16M | 8.83M | 10.54M | 9.13M | 6.51M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 16.7M | 16.16M | 8.83M | 10.54M | 9.13M | 6.51M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 7.41M | 11.44M | 14.51M | 12.72M | 12.47M | 10.96M |
Shares Outstanding (Diluted) | 7.41M | 11.48M | 14.51M | 12.72M | 12.47M | 10.96M |
EPS (Basic) | -1.85 | -1.36 | -0.58 | -0.83 | -0.73 | -0.58 |
EPS (Diluted) | -1.85 | -1.36 | -0.58 | -0.83 | -0.73 | -0.58 |
EBITDA | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | n/a |
EBIT | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.51M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | 6.51M |
Add to Watchlist
Select watchlists to add or remove MNPR